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with low-risk myocardial infarction. METHODS: The partici-
pants in this 12-month prospective study were 153 consecutive
patients with low-risk myocardial infarction (MI) referred to
their primary care center for follow-up care. Of these patients,
113 were referred to a mixed primary and specialized care
program that included physical exercise, cardiovascular risk
control, an antismoking program, health education talks and
psychological evaluation. The other 40 patients served as con-
trols. We analyzed the results after three months and 1 year of
follow-up. RESULTS: There were no differences between the two
groups at baseline. After 1 year, improvements were seen in
smoking habit (4.6% vs. 15.6%; P < 0.05) and body mass index
(26 [2] vs. 29 [2]; P < 0.05). Dyslipidemia, glucose and blood
pressure were similar in both groups after follow-up. Greater
improvements in the group of patients who participated in the
program were seen after 1 year in quality of life (78 [2] vs. 91
[2]; P < 0.05), exercise capacity (10.3 [2] vs. 8.4 [3]; P < < 0.01)
and return to active employment (84.6% vs. 53.3%; P < 0.05).
CONCLUSIONS: After one year of follow-up, the cardiac reha-
bilitation program coordinated by cardiological and primary
care services for low-risk post-MI patients improved quality of
life, and increased exercise tolerance, active employment, and the
number of participants who quit smoking. The mixed program
also reduced body mass index. These results suggest the need for
similar programs.
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OBJECTIVE: To estimate the direct medical costs in patients at
high risk that suffered an atherotrombotic event (AE), i.e., the
cost of the acute event and the costs related to the disease during
a two year follow up period in patients with myorcardial infarc-
tion and stroke, treated in third care level in private institutions
in the Mexican Health System. METHODS: This is a descrip-
tive observational and multicentric study. Each patient included
in the study cohort has an active medical ﬁle with a complete
record for at least a 2-year period after the AE. This study is
based on an incidence costing approach and only includes the
perspective of the payments. The unitary costs used are those
ofﬁcially published by private institutions. All the amounts are
set in 2005 Mexican pesos. The 2005 exchange rate is 11
Mexican pesos per US dollar. RESULTS: A patient who experi-
ences a stroke stays at least 5 days in Intensive Care. The
expected cost per treated patient with stroke reaches US$7876.
The most important category of cost during the acute phase is
hospitalization (US$3924; 50%). On the other hand, the total
direct cost incurred per patient with acute coronary syndrome
(ACS) is US$3367 per year of follow-up and US$16,381 in the
acute event. The most relevant costs are both pharmacy costs
(US$2354) and revascularization procedures (US$9319). Coro-
nary artery stent implantation is the most common revascular-
ization procedure (70%). CONCLUSIONS: AE are associated
with high costs during the years after the acute event, in special
high incidence of hospitalization and drug cost. These results,
especially the proportions between cost items, are consistent with
international studies. Effective prevention and treatment of AE
should be targeted not only on patients and medical profession-
als but also on health decision makers.
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OBJECTIVE: To estimate the long-term economic and health
impact of managing bradycardia due to sinoatrial node disease
or atrioventricular block with a dual (DDD or DDDR) vs. single
chamber ventricular pacemaker (VVI or VVIR). METHODS: A
discrete event simulation was constructed to evaluate the out-
comes over ﬁve years. During the simulation, each patient may
develop post-operative complications, severe pacemaker syn-
drome leading to replacement of the VVI(R) with DDD(R), atrial
ﬁbrillation (which may become chronic and require anticoagu-
lants), or have a stroke. A time for each event is sampled from
the distribution of failure times speciﬁed by the individual’s risk
proﬁle. Life expectancy was estimated and assumed the same
with either device. Model risk functions are based on long-term
randomized trials (Canadian Trial of Physiological Pacing and
Mode Selection Trial in Sinus-Node Dysfunction). Probabilistic
sensitivity analyses were performed for key input parameters.
Direct medical costs are reported in 2004 Euros (€). Beneﬁts and
costs are discounted at 3% per year. RESULTS: Chronic atrial
ﬁbrillation was estimated to be 24% lower with DDD(R). Dis-
counted costs over 5 years were about €10,000 per patient in
either cohort, mean net additional cost of €106 with DDD(R).
DDD(R) led to 0.09 additional QALY; a mean cost-effectiveness
ratio of €1177/QALY, with 21% of replications indicating dom-
inance for DDD(R). Severe pacemaker syndrome requiring
switch to DDD(R) occurred in 16.8% with VVI(R); the results
are sensitive to the proportion that would seek replacement.
CONCLUSION: Lower initial costs with VVI(R) were offset by
second operations to switch to DDD(R) and costs of atrial ﬁb-
rillation. Thus, dual chamber pacemakers are economically
attractive in management of patients with bradycardia.
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OBJECTIVES: To evaluate short-term cost-effectiveness (cost-
utility) of cilostazol for the treatment of intermittent claudica-
tion from the perspective of the Scottish NHS. METHODS: A
decision analytic model was constructed and analysed from the
perspective of the Scottish NHS. Costs include direct medical
costs including drug costs -evaluated at retail prices excluding
taxes, and treatment costs. Treatment costs included the cost of
primary and specialist care of intermittent claudication patients
based on an independent survey of expert clinical opinion in
Scotland. Short- term effectiveness was based on two published
24 week randomised clinically controlled trials of cilostazol 
(100mg) versus placebo. Placebo was chosen as the comparator
since the majority of patients in Scotland do not currently receive
intermittent claudication- speciﬁc medical treatment. Health-
related quality of life was measured in the trials using the SF-36;
these scores were translated into utilities using a validated
mapping algorithm. QALYs were estimated over various scenar-
ios including the base-case analysis of the most conservative
assumption of immediate return to placebo utility post treat-
ment. RESULTS: The incremental cost- utility ratio for cilosta-
zol over placebo was estimated at approximately £12,500 per
QALY. The data were not discounted due to the short time
